Ticagrelor in Comparison to Prasugrel for Inhibition of Platelet Reactivity, in Patients With Acute Coronary Syndrome (ACS) Presenting Resistance to the Usual Clopidogrel Dose After PCI.

Trial Profile

Ticagrelor in Comparison to Prasugrel for Inhibition of Platelet Reactivity, in Patients With Acute Coronary Syndrome (ACS) Presenting Resistance to the Usual Clopidogrel Dose After PCI.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2012

At a glance

  • Drugs Ticagrelor (Primary) ; Prasugrel
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Jul 2012 Primary endpoint 'Platelet-function' has been met.
    • 17 Jul 2012 Results published in the Journal of the American College of Cardiology.
    • 27 Mar 2012 Results presented at the 61st Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top